Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Feb 03, 2024 12:32pm
90 Views
Post# 35861200

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studied

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studiedwhat a pity that Pela doesn't cure delusions...  

You are so wrong Noteable its almost beyond ridiculous... but the shameful thing is you keep stating that the ones challenging the pumpers on this bb are part of some scheme to aquire ONCY on the cheap... well, If ONCY were to release data that unassailably demonstrates with statisitical significance that Pela in combo is effective in treating Panc and mBC patients then the price wouldn't be so cheap... year after year we wait on Phase II trials for which no prove can be taken because they are underpowered.

IND-213 was a randomised Phase II trial, FDA awarded ONCY with a SPA at the end of Phase II meeting, and all ONCY had to do was then re-run IND-213 with 450 or so patients in a Phase III... that was 2018... so it is ONCY mismanagement and their inablility to generate BD interest that has left this company's stock price floundering... NOT the few of us here who have been pointing this out.

Either prove your accusations, or desist.
<< Previous
Bullboard Posts
Next >>